Mefenamic Acid Shows Neuroprotective Effects and Improves Cognitive Impairment in in Vitro and in Vivo Alzheimer's Disease Models

  title={Mefenamic Acid Shows Neuroprotective Effects and Improves Cognitive Impairment in in Vitro and in Vivo Alzheimer's Disease Models},
  author={Yuyoung Joo and Hye-Sun Kim and Ran-Sook Woo and Cheol Hyoung Park and Ki Young Shin and Jean-Pyo Lee and Keun-A Chang and Seong Hun Kim and Yoo-hun Suh},
  journal={Molecular Pharmacology},
  pages={76 - 84}
Nonsteroidal anti-inflammatory drugs (NSAIDs) exert anti-inflammatory, analgesic, and antipyretic activities and suppress prostaglandin synthesis by inhibiting cyclooxygenase, an enzyme that catalyzes the formation of prostaglandin precursors from arachidonic acid. Epidemiological observations indicate that the long-term treatment of patients suffering from rheumatoid arthritis with NSAIDs results in reduced risk and delayed onset of Alzheimer's disease. In this study, we investigated the… 

Figures from this paper

An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease
  • B. Imbimbo
  • Medicine, Biology
    Expert opinion on investigational drugs
  • 2009
It is hypothesized that the chronic use of NSAIDs may be beneficial only in the normal brain by inhibiting the production of Aβ42, which mediates Aβ clearance and activates compensatory hippocampal neurogenesis.
Mechanisms Underlying Neuroprotection by the NSAID Mefenamic Acid in an Experimental Model of Stroke
In vitro, the fenamates, MFA, meclofenamic acid, niflumic acid, and flufenamic Acid each reduced glutamate-evoked excitotoxicity in cultured embryonic rat hippocampal neurons supporting the idea that this is a drug class action.
It can be concluded that NSAIDs provide its neuroprotective activity on its long-term use only, as the brain accessibility of this kind of drug is poor due to its lower lipophilicity.
Improve cognitive impairment using mefenamic acid non-steroidal anti-inflammatory therapy: additional beneficial effect found in a controlled clinical trial for prostate cancer therapy.
This study is the first conducted on humans that suggests that mefenamic acid protects against cognitive decline and significantly increases the probability of maintained or raised cognitive function compared to placebo.
Tacrine-mefenamic acid hybrids for inhibition of acetylcholinesterase
A convergent chemical synthetic approach yielded a series of tacrine-mefenamic acid hybrids that were evaluated for their ability to inhibit acetylcholinesterase (AChE) and may suggest a role for the mefenamic acid moiety in the inhibition of AChE.
Alzheimer's disease as an autoimmune disorder of innate immunity endogenously modulated by tryptophan metabolites
Conceptualizing AD as an autoimmune disease, identifying endogenous regulators of this autoimmunity, and designing small molecule drug‐like analogues of these endogenous regulators represents a novel therapeutic approach for AD.
Inflammasomes as therapeutic targets for Alzheimer's disease
NLRP3 and NLRP1 inflammasomes have been found to be integral in pathogenic neuroinflammation in animal models of Alzheimer's disease and are very promising novel pharmacological targets which merit further research in the continued endeavor for efficacious therapeutics for Alzheimer’s disease.
Neuregulin-1 protects against neurotoxicities induced by Swedish amyloid precursor protein via the ErbB4 receptor


Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity.
Results strongly suggest that NSAIDs represent a founding group of compounds that lower A beta 42 production by direct modulation of gamma-secretase activity or its substrate.
Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid β42 Production by Direct Modulation of γ-Secretase Activity*
Results strongly suggest that NSAIDs represent a founding group of compounds that lower Aβ42 production by direct modulation of γ-secretase activity or its substrate.
Anti-Inflammatory Drug Therapy Alters β-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease
Data show that chronic NSAID treatment can reduce brain Aβ levels, amyloid plaque burden, and microglial activation in an animal model of Alzheimer's disease.
New anti-inflammatory treatment strategy in Alzheimer's disease.
It is proposed that the 5- LOX inflammatory cascade may take part in the process of aging-associated neurodegenerative diseases, and the role of 5-LOX in Neurodegeneration is pointed to and its relevance for anti-inflammatory therapy of AD is discussed.
Carboxyl‐terminal fragment of Alzheimer's APP destabilizes calcium homeostasis and renders neuronal cells vulnerable to excitotoxicity
  • H. Kim, C. H. Park, Y. Suh
  • Biology, Chemistry
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 2000
The results of this study showed that CT 105 disrupts calcium homeostasis and renders neuronal cells more vulnerable to glutamate‐induced excitotoxicity, and that some portion of CT 105 has partial β‐sheet conformation in various environments, which may be related to the self‐aggregation and toxicity.
Neuroprotective effects of non‐steroidal anti‐inflammatory drugs by direct scavenging of nitric oxide radicals
The results suggest that the protective effects of the former four non‐steroidal anti‐inflammatory drugs against apoptosis might be mainly due to their direct nitric oxide radical scavenging activities in neuronal cells.
Amyloid β-induced Changes in Nitric Oxide Production and Mitochondrial Activity Lead to Apoptosis*
A hypothetical sequence of pathogenic steps linking mutant APP expression and amyloid production with enhanced NO production and mitochondrial dysfunction finally leading to cell death is suggested, indicating a direct involvement of Aβ in these processes.
Anti‐Inflammatory Drugs in the Fight against Alzheimer's Disease a
Data imply that an autodestructive process is occurring in Alzheimer's disease, and that anti‐inflammatory drugs might be an effective form of therapy, and some epidemiological evidence and results of a pilot clinical trial support this hypothesis.
Cytokines in neuroinflammation and Alzheimer's disease.
Inflammation has been reported in numerous neurodegenerative disorders such as Parkinson's disease, stroke and Alzheimer's disease and these cytokines should be considered as key players of a vicious circle leading to the progression of the disease.
Amyloid Precursor Protein, Presenilins, and α-Synuclein: Molecular Pathogenesis and Pharmacological Applications in Alzheimer's Disease
Treatments that block the accumulation of Aβ and α-synuclein might benefit a broad spectrum of neurodegenerative disorders, because some patients have clinical and pathological features of both diseases, raising the possibility of overlapping pathogenic pathways.